Anthem Blue Cross ConnecticutCommercial Clinical Policy

LAB.00028 Blood-based Biomarker Tests for Multiple Sclerosis Form

Chat with GenHealth to automate any policy or prior auth task.

Effective Date

09/27/2023

Last Reviewed

08/10/2023

Original Document

  Reference



This document addresses blood-based biomarker tests for multiple sclerosis (MS). Examples are:

  • gMS® Dx (Glycominds, Simi Valley, CA)
  • gMS® Pro EDSS (Glycominds, Simi Valley, CA)
  • Neurofilament light chain

Blood-based biomarker tests for MS are blood tests designed to either expedite the diagnosis of MS or as a prognostic tool to measure the risk for rapid progression of disability in individuals with relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS).

Position Statement

Investigational and Not Medically Necessary:

Blood-based biomarker tests for multiple sclerosis are considered investigational and not medically necessary for all uses.

Book a walkthrough

Walk through this policy with us

Review how this policy can be converted into cited criteria, prior authorization checks, and operational automation.